Atorvastatin For The Reduction Of Ventricular Arrhythmias
Atorvastatin For The Reduction Of Ventricular Arrhythmias
To assess in patients with CAD [coronary artery disease] and an implantable defibrillator the
 effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular
 arrhythmia (ventricular tachycardia or ventricular fibrillation requiring ICD [implantable
 cardioverter defibrillator] intervention) within one year after randomization.
Inclusion Criteria:

 -  Eligible subjects were male or female subjects, age >18 years, with clinically
 documented coronary artery disease and life-threatening ventricular arrhythmias who
 met the following criteria:

 -  Were scheduled for an ICD implantation or had an ICD implantation within 1 month,
 according to the class I American College of Cardiology/American Heart Association
 (ACC/AHA) practice guidelines for ICD therapy

 OR

 -  Were already treated with an ICD for a class I ACC/AHA indication for more than one
 month, provided they received at least one appropriate ICD intervention (shock or
 antitachycardia pacing (ATP) for ventricular tachycardia or ventricular fibrillation)
 during the preceding six months

 Exclusion Criteria:

 -  Patients with ventricular arrhythmias in the acute phase of myocardial infarction
 (first 48 hours).

 -  Patients with incessant ventricular tachycardia.

 -  Patients with ventricular arrhythmias without underlying coronary artery disease.

 -  Patients with a transient or reversible cause of ventricular arrhythmias (including
 significant electrolyte disturbances or drug induced proarrhythmia).